drugset / Trial / NCT03675139
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
RandomizedParallel-groupSingle-blindTreatment
Summary
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
Timeline
- Start
- 2019-02-26
- Primary completion
- 2022-05-14
- Completion
- 2022-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dydrogesterone | Other / unclassified | 20 mg | Oral |
| Subject | medroxyprogesterone acetate | Other / unclassified | 10 mg | Oral |